DOCSLIB.ORG

Highly Complementary with an Overlap of ~6% in the Number of Unique, Non-Redundant Phosphopeptide Identifications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Highly Complementary with an Overlap of ~6% in the Number of Unique, Non-Redundant Phosphopeptide Identifications Charles L. Farnsworth, Hongbo Gu, Xiaoying Jia, Jian Min Ren, Kimberly Lee, Jeffrey C. Silva Demonstration of Orthogonal Complementary Enrichment Methods for Cell Signaling Technology, Inc., Danvers MA 01923 Enhanced Phosphopeptide Profiling of Drug-Treated Gastric Carcinoma Cells A B C MW 1 2 3 MW 1 2 3 MW 1 2 3 CS 20697 Peak Height Average Fold Change Introduction Peak Height Average Fold Change Phospho-tyrosine A DMSO Met Y1003 175 - 175 - 175 - The post-translational modification of proteins by phosphorylation has been shown to regulate many aspects of cellular function from SVSPTTEMVSNIESVDY*R 17,144,71617,144,716 16,403,20016,403,200 15,661,685 All Antibodies growth and differentiation to basic metabolism. Here we show that two phosphopeptide enrichment strategies (IMAC and Motif Anti- m/z 990.9165 CS 20698 15,661,685 83 - 83 - DMSO body) are highly complementary with an overlap of ~6% in the number of unique, non-redundant phosphopeptide identifications. In 83 - - p-p90RSK S380 (5,727) 62 - 62 - - p-pAKT S473 conjunction with using label-free quantitation methods, we show effects of two classes of kinase inhibitor on down stream substrates 100 62 - CS 20699 SU11274 in the human gastric carcinoma cell line, MKN-45. Following treatment of cells with the c-Met RTK inhibitor SU11274 or the PKC 47.5 - 47.5 - 80 47.5 - - p-Erk T204 Y204 851,000851,000 902,100902,100 -18.8-18.8 60 3.8% 1.4% family inhibitor staurosporine, phosphopeptides were isolated using a combination of 14 serine and threonine phospho specific motif Peak 953,200 Height 953,200 (13,480) 32.5 - 32.5 - 40 CS 20700 antibodies, a Phospho-Tyrosine specific rabbit monoclonal antibody or an IMAC enrichment using Fe3+ charged agarose beads. The - p-S6 S234/235 Relative Intensity Peak SU11274 32.5 - 20 Area 25 - 25 - - Rab11 results show over 20,000 unique phosphopeptides were identified with these methods. 0 25 - 23 24 25 26 27 Time (s) CS 20701 Staurosporine Basophillic IMAC Proline 10,598,341 10,037,265 -1.6 16.5 - 16.5 - 10,598,341 10,037,265 -1.6 Mix (2,427) (13,892) (3,154) Mix 9,476,1909,476,190 5.6% 16.5 - 6.5 - 6.5 - CS 20702 Methods Staurosporine The gastric cancer cell line MKN-45 was treated with vehicle, SU11274 or staurosporine for 2 hours. Tryptic and LysC pep- Phospho-tyrosine (P-Tyr-1000) Phospho-Met (Tyr1234/1235) PathScan® Multiplex tides were generated from control and treated cellular extracts. Phosphopeptide enrichments were performed using a com- Rabbit mAb #8954 (D26) XP® Rabbit mAb #3077 Western Cocktail I #5301 3.2% 2.6% 3+ (13,892) bination of motif antibodies and Fe charged NTA agarose beads. Purified peptides were analyzed by LC-MS/MS using Figure 7: Label-Free Quantitation. Phosphopeptides were quantified based on MS1 peak height or area an Orbitrap Velos™ (Thermo Fisher Scientific Inc.); phospho-serine/threonine and tyrosine peptides were identified using Figure 4: Control Western Blots. A total of 20 μg of protein per condition was used for western blot analy- measurements, and expressed as ratios of treated as compared to DMSO control. Peak integration was (3,818) SEQUEST (The Scripps Research Institute, La Jolla, CA). Label-free quantification was used to perform relative quanti- sis (lane 1- DMSO, lane 2- SU11274, lane 3- staurosporine). The following western blots are illustrated above: fication for all identified phosphopeptides. Quantitative label-free quantification was performed using Skyline Software performed using either XCalibur or Skyline software. (A) Phospho-tyrosine antibody; (B) Phospho-Met Y1234/1235; (C) PathScan® multiplex western cocktail. (MacCoss Lab Software, University of Washington, Seattle, Washington); results were analyzed using TIBCO Spotfire DecisionSite IMAC Serine/Threonine Mix software (TIBCO Software, Inc., Palo Alto, CA). B A B C D 8 8 MW 1 2 3 MW 1 2 3 MW 1 2 3 MW 1 2 3 6 SU 6 ST Figure 10: Qualitative Comparison of IMAC and Motif Antibody Analaysis. A total of 27,372 4 4 Figure 1: Study Design. A total of 175 - 2 2 unique phosphopeptides were isolated from the combined IMAC and motif antibody enrichment strategies. 175 - 175 - 8 175 - 0 0 The Venn intersection between the different methods is shown. The non-redundant number of phosphopep- Experimental Outline 1X10 MKN-45 cells per experiment -2 -2 Phospho-tyrosine 83 - MKN-­‐45 Cells were treated as described above. 83 - 83 - -4 -4 tides for each enrichment strategy are in brackets. The percent shared between each method is shown at 83 - -6 -6 10 dishes 10 dishes 10 dishes 62 - The cells were harvested in urea lysis -8 -8 the intersection. 62 - 62 - 62 - buffer, reduced, alkylated and digested 47.5 - -10 -10 DMSO SU11274 Stuarosporine 47.5 - 47.5 - 47.5 - with LysC or trypsin using standard 8 8 32.5 - 6 SU 6 ST Serine/Threonine Mix 32.5 - 32.5 - 32.5 - methods (Rush et al.) prior to immu- 25 - 4 4 25 - 25 - noaffinity enrichment. 25 - 2 2 0 0 Harvested in urea lysis buffer Basophilic -2 -2 -4 -4 25mg trypsin/25mg LysC (Ratio) -6 -6 (3,818) 2 17.8% PKC Substrate Motif AKT Substrate Motif AMPK/PKD Substrate Motif MAPK Substrate Motif -8 -8 5mg and 1mg aliquots (P-S3-101) (RXXS*/T*) / (RXRXXS*/T*) (P-S/T2-102) / PKD Substrate (PXS* or S* PXR/K) -10 -10 #6967 #9614 / #10001 #5759 / #4381 #2325 3.3% 8 8 IMAC pY1000 MoMf Ab S/T Basophillic Proline-­‐directed 6 SU 6 ST Figure 5: Motif Antibody Western Blots. Protein extracts were probed with the following kinase Orbitrap Elite; Replicate InjecMons 4 4 substrate motif antibodies: (A) PKC, (B) Akt, (C) AMPK and PKD, (D) MAPK. 2 2 (3,154) Proline 0 0 Serine-threonine Mix -2 -2 Basophillic (2,427) -4 -4 Mix Phospho-Motif Antibodies Figure 2: Motif Ab List. The follow- Strict -6 -6 Figure 13: KEGG Pathway Analysis. The tyrosine kinase pathway (A), the MAPK kinase pathway (B) -8 -8 Motif Antibody Kinase Family Motif Antibody # Type Number DMSO log Treated: ing substrate motif antibodies were Enrichment Sample Treatment Phosphopeptides Reverse False Discovery Rate -10 -10 1.2% were annotated from a subset of the data generated in this study. Red outline denotes proteins Akt Substrate AGC RXX(s/t) 9614 Baso, ST Mix Pan-tyrosine MKN-45 DMSO 6316 44 1.4% used to enrich for phosphopeptides. 6 8 identified in this study. The pathways are derived from the pathway analysis tool DAVID, from NIAID, Akt Substrate AGC RXRXX(s/t) 10001 Baso, ST Mix Pan-tyrosine MKN-45 DMSO 6445 38 1.2% SU 6 ST Figure 11: Overlap of Motif Antibody Enrichment Strategies. The shared percentage of unique PKA Substrate AGC (K/R)(K/R)X(s/t) 9624 Baso, ST Mix A combination of related motif anti- Pan-tyrosine MKN-45 SU11274 3018 22 1.5% 4 http://david.abcc.ncifcrf.gov/ 4 PKC Substrate AGC (K/R)XsX(K/R) 2261 Baso, ST Mix Pan-tyrosine MKN-45 SU11274 2976 22 1.5% 2 phosphopeptides is shown. The total number per each enrichment strategy is in brackets. bodies were utilized to enrich for 2 Pan-tyrosine MKN-45 Staurosporine 5817 53 1.8% 0 PKD Substrate AGC LXRXP(s/t) 4381 Baso, ST Mix 0 similar motif TYPES as outlined above Pan-tyrosine MKN-45 Staurosporine 5846 31 1.1% -2 Proline CDK Substrate CMGC (K/R)sPX(K/R) 9477 Baso, ST Mix -2 -4 AMPK LxRXX(s/t) Baso, ST Mix (pY, S/T Mix, Basophilic & Proline- -4 CAMKL 5759 Basophillic MKN-45 DMSO 2167 25 2.3% Conclusion -6 -6 Normalized Fold Change pY1000 Tyrosine xYX 8954 pY Directed). Basophillic MKN-45 DMSO 2233 19 1.7% -8 -8 The enrichment strategies used here demonstrate the high degree of complementarity between metal based IMAC and substrate ATM/ATR Substrate Atypical (s/t)QG, sQ 6966, 9607 ST Mix Basophillic MKN-45 SU11274 1886 32 3.4% SU11274: Staurosporine: -10 -10 DMSO DMSO Protein Name Site -­‐7/+ 7 PepCde Upstream Kinase motif antibodies in the identification of phosphopeptides. CK2 Substrate CK1 t(D/E)X(D/E) 8738 ST Mix Basophillic MKN-45 SU11274 1912 19 2.0% -5.0 -4.6 EphA2 897% RVSIRLPsTSGSEGV! LPS*T*SGSEGVPFR Akt1 Basophillic MKN-45 Staurosporine 2053 34 3.3% -13.6 -2.1 FOXO1A %319 TSS*NASTISGR Akt1 MAPK Substrate MAPK PXsP 2325 Proline, ST Mix TFRPRTSsNASTISG! Substrate motif antibodies can be used in western blotting to pre-screen samples for qualitative evaluation of response to treatment Average peptide intensity log10 -158.0 -7.2 FOXO4 %32 QSRPRSCtWPLPRPE! SCT*WPLPRPEIANQPSEPPEVEPDLGEK Akt1 Basophillic MKN-45 Staurosporine 1988 24 2.4% ® tP Motif Proline Based tP, tPP 8134 Proline, ST Mix -3.4 1.8 QIK %358 DGRQRRPsTIAEQTV! RPS*TIAEQTVAK Akt1, Akt2 prior to PhosphoScan . tPE Motif Proline Based tPE, tP 3004 Proline, ST Mix -13.3 -29.4 S6 %235, %236, %240 IAKRRRLsSLRASTS! RLS*S*LRAS*TSK Akt1, Akt2, P70S6KB, PKACA, PKCA, PKCD S/T Mix MKN-45 DMSO 4024 78 3.8% -7.0 -24.5 S6 %236, %240 AKRRRLSsLRASTSK! RLSS*LRAS*TSK Akt1, Akt2, P70S6KB, PKACA, PKCA, PKCD PLK Binding motif Proline Based StP 5243 Figure 8: Relative Quantitation for SU11274 and Staurosporine Treated MKN-45 Cells. Scatter Proline, ST Mix S/T Mix MKN-45 DMSO 4057 93 4.5% 2.6 1.1 BRAF %365 GQRDRSSsAPNVHIN! SSS*APNVHINTIEPVNIDDLIR Akt1, Akt3 Presentation Posters, tXR Motif Proline Based tXR, tPR 8139 Proline, ST Mix S/T Mix MKN-45 SU11274 3685 107 5.6% plots are illustrated for the relative quantitation of SU11274 and Staurosporine-treated MKN-45 cells -7.0 -9.4 GSK3B 9% SGRPRTTsFAESCKP! TTS*FAESCKPVQQPSAFGSMK Akt1, AurA, CAMK2B, GSK3B, KHS1, PKACA, PKCA Case Studies and Publications -5.3 N.D.
Load more

Recommended publications
  • Supplemental Information to Mammadova-Bach Et Al., “Laminin Α1 Orchestrates VEGFA Functions in the Ecosystem of Colorectal Carcinogenesis”
    Supplemental information to Mammadova-Bach et al., “Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinogenesis” Supplemental material and methods Cloning of the villin-LMα1 vector The plasmid pBS-villin-promoter containing the 3.5 Kb of the murine villin promoter, the first non coding exon, 5.5 kb of the first intron and 15 nucleotides of the second villin exon, was generated by S. Robine (Institut Curie, Paris, France). The EcoRI site in the multi cloning site was destroyed by fill in ligation with T4 polymerase according to the manufacturer`s instructions (New England Biolabs, Ozyme, Saint Quentin en Yvelines, France). Site directed mutagenesis (GeneEditor in vitro Site-Directed Mutagenesis system, Promega, Charbonnières-les-Bains, France) was then used to introduce a BsiWI site before the start codon of the villin coding sequence using the 5’ phosphorylated primer: 5’CCTTCTCCTCTAGGCTCGCGTACGATGACGTCGGACTTGCGG3’. A double strand annealed oligonucleotide, 5’GGCCGGACGCGTGAATTCGTCGACGC3’ and 5’GGCCGCGTCGACGAATTCACGC GTCC3’ containing restriction site for MluI, EcoRI and SalI were inserted in the NotI site (present in the multi cloning site), generating the plasmid pBS-villin-promoter-MES. The SV40 polyA region of the pEGFP plasmid (Clontech, Ozyme, Saint Quentin Yvelines, France) was amplified by PCR using primers 5’GGCGCCTCTAGATCATAATCAGCCATA3’ and 5’GGCGCCCTTAAGATACATTGATGAGTT3’ before subcloning into the pGEMTeasy vector (Promega, Charbonnières-les-Bains, France). After EcoRI digestion, the SV40 polyA fragment was purified with the NucleoSpin Extract II kit (Machery-Nagel, Hoerdt, France) and then subcloned into the EcoRI site of the plasmid pBS-villin-promoter-MES. Site directed mutagenesis was used to introduce a BsiWI site (5’ phosphorylated AGCGCAGGGAGCGGCGGCCGTACGATGCGCGGCAGCGGCACG3’) before the initiation codon and a MluI site (5’ phosphorylated 1 CCCGGGCCTGAGCCCTAAACGCGTGCCAGCCTCTGCCCTTGG3’) after the stop codon in the full length cDNA coding for the mouse LMα1 in the pCIS vector (kindly provided by P.
    [Show full text]
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Coupling of Autism Genes to Tissue-Wide Expression and Dysfunction of Synapse, Calcium Signalling and Transcriptional Regulation
    PLOS ONE RESEARCH ARTICLE Coupling of autism genes to tissue-wide expression and dysfunction of synapse, calcium signalling and transcriptional regulation 1 2,3 4 1,5 Jamie ReillyID *, Louise Gallagher , Geraldine Leader , Sanbing Shen * 1 Regenerative Medicine Institute, School of Medicine, Biomedical Science Building, National University of a1111111111 Ireland (NUI) Galway, Galway, Ireland, 2 Discipline of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland, 3 Trinity Translational Medicine Institute, Trinity Centre for Health SciencesÐTrinity College a1111111111 Dublin, St. James's Hospital, Dublin, Ireland, 4 Irish Centre for Autism and Neurodevelopmental Research a1111111111 (ICAN), Department of Psychology, National University of Ireland (NUI) Galway, Galway, Ireland, a1111111111 5 FutureNeuro Research Centre, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland a1111111111 * [email protected] (JR); [email protected] (SS) Abstract OPEN ACCESS Citation: Reilly J, Gallagher L, Leader G, Shen S Autism Spectrum Disorder (ASD) is a heterogeneous disorder that is often accompanied (2020) Coupling of autism genes to tissue-wide with many co-morbidities. Recent genetic studies have identified various pathways from expression and dysfunction of synapse, calcium hundreds of candidate risk genes with varying levels of association to ASD. However, it is signalling and transcriptional regulation. PLoS ONE unknown which pathways are specific to the core symptoms or which are shared by the co- 15(12): e0242773. https://doi.org/10.1371/journal. pone.0242773 morbidities. We hypothesised that critical ASD candidates should appear widely across dif- ferent scoring systems, and that comorbidity pathways should be constituted by genes Editor: Nirakar Sahoo, The University of Texas Rio Grande Valley, UNITED STATES expressed in the relevant tissues.
    [Show full text]
  • Calmodulin and Calmodulin-Dependent Protein Kinase II Inhibit Hormone Secretion in Human Parathyroid Adenoma
    31 Calmodulin and calmodulin-dependent protein kinase II inhibit hormone secretion in human parathyroid adenoma Ming Lu1,2,3, Erik Berglund1, Catharina Larsson1,3, Anders Ho¨o¨g4, Lars-Ove Farnebo1 and Robert Bra¨nstro¨m1 1Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital L1:03, SE-171 76 Stockholm, Sweden 2Department of Geriatric Endocrinology, First Affiliated Hospital of Guangxi Medical University, NanNing, People’s Republic of China 3Center for Molecular Medicine (CMM), Karolinska University Hospital, SE-171 76 Stockholm, Sweden 4Department of Oncology–Pathology, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden (Correspondence should be addressed to M Lu at Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital; Email: [email protected]) Abstract 2C 2C Intracellular calcium ([Ca ]i) is the most relevant modulator adenoma cells in spite of increased [Ca ]i. The inhibitory C of parathyroid hormone (PTH) secretion. Uniquely, an effect of Ca2 calmodulin on PTH secretion may be due to 2C increase in [Ca ]i results in an inhibition of PTH secretion, the absence of synaptotagmin 1 protein in parathyroid and it probably exerts its function via calcium-binding protein adenomas, as demonstrated by western blot analysis. An pathways. The ubiquitous calcium-binding proteins, calmo- increased extracellular calcium level acutely lowered the dulin and calmodulin-dependent protein kinase II (CaMKII), amount of active phosphorylated CaMKII (pCaMKII) in have well-established roles in regulated exocytosis in neurons adenoma cells in vitro, indicating the physiological importance and neuroendocrine cells. However, their roles in parathyroid of this pathway. Moreover, a negative correlation between the cells and PTH secretion are still unclear.
    [Show full text]
  • Profiling Data
    Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8
    [Show full text]
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]
  • Novel Insights Into Neuronal CAMK2 Function
    Novel Insights Novel UITNODIGING voor het bijwonen van de openbare verdediging into Neuronal CAMK2 Function CAMK2 Neuronal into van het proefschrift Novel Insights into Neuronal CAMK2 Function door Martijn J. Kool op dinsdag 11 december 2018 om 13:30 Professor Queridozaal Onderwijscentrum Erasmus MC Dr. Molewaterplein 40 3015 CD Rotterdam MARTIJN KOOL Moutersteeg 11 3024 RG Rotterdam Novel Insights [email protected] into Neuronal PARANIMFEN CAMK2 Function Thomas Hulst Martijn J. Kool [email protected] Laura-anne Grimbergen [email protected] Martijn J. Kool 15932-kool-cover.indd 1 22/10/2018 09:38 NOVEL INSIGHTS INTO NEURONAL CAMK2 FUNCTION Martijn Jacob Kool COLOFON Cover design: Front: "Hippocampus and CAMK2" by Jan Berkelouw Back: "Two Pyramidals" by Greg Dunn Layout: Design Your Thesis, www.designyourthesis.com Printing: Ridderprint B.V., www.ridderprint.nl ISBN: 978-94-6375-178-0 Copyright © 2018 by Martijn Jacob Kool. All rights reserved. Any unauthorized reprint or use of this material is prohibited. No part of this thesis may be reproduced, stored or transmitted in any form or by any means, without written permission of the author or, when appropriate, of the publishers of the publications. NOVEL INSIGHTS INTO NEURONAL CAMK2 FUNCTION NIEUWE INZICHTEN IN DE FUNCTIE VAN NEURONAAL CAMK2 PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. R.C.M.E. Engels en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op 11 december 2018 om 13:30 uur door Martijn Jacob Kool geboren te Rotterdam PROMOTIECOMMISSIE Promotor: Prof.dr.
    [Show full text]
  • Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in Vitro and in Vivo
    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Genetik Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in vitro and in vivo - Towards Response Prediction in Cancer Therapy with Kinase Inhibitors Michaela Bairlein Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ. -Prof. Dr. K. Schneitz Prüfer der Dissertation: 1. Univ.-Prof. Dr. A. Gierl 2. Hon.-Prof. Dr. h.c. A. Ullrich (Eberhard-Karls-Universität Tübingen) 3. Univ.-Prof. A. Schnieke, Ph.D. Die Dissertation wurde am 07.01.2010 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 19.04.2010 angenommen. FOR MY PARENTS 1 Contents 2 Summary ................................................................................................................................................................... 5 3 Zusammenfassung .................................................................................................................................................... 6 4 Introduction .............................................................................................................................................................. 8 4.1 Cancer ..............................................................................................................................................................
    [Show full text]
  • Anti-CAMK2B Monoclonal Antibody (DCABH- 10166) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Anti-CAMK2B monoclonal antibody (DCABH- 10166) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Product Overview Mouse monoclonal to CaMKII beta Antigen Description CaM-kinase II (CAMK2) is a prominent kinase in the central nervous system that may function in long-term potentiation and neurotransmitter release. Member of the NMDAR signaling complex in excitatory synapses, it may regulate NMDAR-dependent potentiation of the AMPAR and synaptic plasticity. Immunogen Recombinant fragment: FEPEALGNLV EGMDFHRFYF ENLLAKNSKP IHTTILNPHV HVIGEDAACI AYIRLTQYID GQGRPRTSQS EETRVWHRRD GKWQNVHFHC SGAPVAPL, corresponding to amino acids 405-502 of human CaMKII beta (NP_742078) with a proprietary tag. Isotype IgG1 Source/Host Mouse Species Reactivity Rat, Human Purity Protein A purified Conjugate Unconjugated Applications WB, ELISA, ICC/IF, Flow Cyt Positive Control WB: The immunogen; HeLa and PC12 cell lysates ICC/If: HeLa cell Format Liquid Size 100 μg Buffer Preservative: None; Constituents: 1X PBS, pH 7.2 Preservative None Storage store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. Ship Shipped at 4°C. 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved GENE INFORMATION Gene Name CAMK2B calcium/calmodulin-dependent protein kinase II beta [ Homo sapiens ] Official Symbol CAMK2B Synonyms CAMK2B; calcium/calmodulin-dependent protein kinase II beta; calcium/calmodulin dependent protein
    [Show full text]
  • Systems-Level Identification of PKA-Dependent Signaling In
    Systems-level identification of PKA-dependent PNAS PLUS signaling in epithelial cells Kiyoshi Isobea, Hyun Jun Junga, Chin-Rang Yanga,J’Neka Claxtona, Pablo Sandovala, Maurice B. Burga, Viswanathan Raghurama, and Mark A. Kneppera,1 aEpithelial Systems Biology Laboratory, Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1603 Edited by Peter Agre, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, and approved August 29, 2017 (received for review June 1, 2017) Gproteinstimulatoryα-subunit (Gαs)-coupled heptahelical receptors targets are as yet unidentified. Some of the known PKA targets regulate cell processes largely through activation of protein kinase A are other protein kinases and phosphatases, meaning that PKA (PKA). To identify signaling processes downstream of PKA, we de- activation is likely to result in indirect changes in protein phos- leted both PKA catalytic subunits using CRISPR-Cas9, followed by a phorylation manifest as a signaling network, the details of which “multiomic” analysis in mouse kidney epithelial cells expressing the remain unresolved. To identify both direct and indirect targets of Gαs-coupled V2 vasopressin receptor. RNA-seq (sequencing)–based PKA in mammalian cells, we used CRISPR-Cas9 genome editing transcriptomics and SILAC (stable isotope labeling of amino acids in to introduce frame-shifting indel mutations in both PKA catalytic cell culture)-based quantitative proteomics revealed a complete loss subunit genes (Prkaca and Prkacb), thereby eliminating PKA-Cα of expression of the water-channel gene Aqp2 in PKA knockout cells. and PKA-Cβ proteins. This was followed by use of quantitative SILAC-based quantitative phosphoproteomics identified 229 PKA (SILAC-based) phosphoproteomics to identify phosphorylation phosphorylation sites.
    [Show full text]
  • Inhibition of ERK 1/2 Kinases Prevents Tendon Matrix Breakdown Ulrich Blache1,2,3, Stefania L
    www.nature.com/scientificreports OPEN Inhibition of ERK 1/2 kinases prevents tendon matrix breakdown Ulrich Blache1,2,3, Stefania L. Wunderli1,2,3, Amro A. Hussien1,2, Tino Stauber1,2, Gabriel Flückiger1,2, Maja Bollhalder1,2, Barbara Niederöst1,2, Sandro F. Fucentese1 & Jess G. Snedeker1,2* Tendon extracellular matrix (ECM) mechanical unloading results in tissue degradation and breakdown, with niche-dependent cellular stress directing proteolytic degradation of tendon. Here, we show that the extracellular-signal regulated kinase (ERK) pathway is central in tendon degradation of load-deprived tissue explants. We show that ERK 1/2 are highly phosphorylated in mechanically unloaded tendon fascicles in a vascular niche-dependent manner. Pharmacological inhibition of ERK 1/2 abolishes the induction of ECM catabolic gene expression (MMPs) and fully prevents loss of mechanical properties. Moreover, ERK 1/2 inhibition in unloaded tendon fascicles suppresses features of pathological tissue remodeling such as collagen type 3 matrix switch and the induction of the pro-fbrotic cytokine interleukin 11. This work demonstrates ERK signaling as a central checkpoint to trigger tendon matrix degradation and remodeling using load-deprived tissue explants. Tendon is a musculoskeletal tissue that transmits muscle force to bone. To accomplish its biomechanical function, tendon tissues adopt a specialized extracellular matrix (ECM) structure1. Te load-bearing tendon compart- ment consists of highly aligned collagen-rich fascicles that are interspersed with tendon stromal cells. Tendon is a mechanosensitive tissue whereby physiological mechanical loading is vital for maintaining tendon archi- tecture and homeostasis2. Mechanical unloading of the tissue, for instance following tendon rupture or more localized micro trauma, leads to proteolytic breakdown of the tissue with severe deterioration of both structural and mechanical properties3–5.
    [Show full text]
  • PRODUCTS and SERVICES Target List
    PRODUCTS AND SERVICES Target list Kinase Products P.1-11 Kinase Products Biochemical Assays P.12 "QuickScout Screening Assist™ Kits" Kinase Protein Assay Kits P.13 "QuickScout Custom Profiling & Panel Profiling Series" Targets P.14 "QuickScout Custom Profiling Series" Preincubation Targets Cell-Based Assays P.15 NanoBRET™ TE Intracellular Kinase Cell-Based Assay Service Targets P.16 Tyrosine Kinase Ba/F3 Cell-Based Assay Service Targets P.17 Kinase HEK293 Cell-Based Assay Service ～ClariCELL™ ～ Targets P.18 Detection of Protein-Protein Interactions ～ProbeX™～ Stable Cell Lines Crystallization Services P.19 FastLane™ Structures ～Premium～ P.20-21 FastLane™ Structures ～Standard～ Kinase Products For details of products, please see "PRODUCTS AND SERVICES" on page 1～3. Tyrosine Kinases Note: Please contact us for availability or further information. Information may be changed without notice. Expression Protein Kinase Tag Carna Product Name Catalog No. Construct Sequence Accession Number Tag Location System HIS ABL(ABL1) 08-001 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) BTN BTN-ABL(ABL1) 08-401-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ABL(ABL1) [E255K] HIS ABL(ABL1)[E255K] 08-094 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) HIS ABL(ABL1)[T315I] 08-093 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) [T315I] BTN BTN-ABL(ABL1)[T315I] 08-493-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ACK(TNK2) GST ACK(TNK2) 08-196 Catalytic domain
    [Show full text]